Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07214519 · ClinicalTrials.gov registry record · NA
Permanent Supportive Housing Overdose Prevention+ Study
A NA study, sponsored by NYU Langone Health.
- Not yet
- Registry status
- NA
- Development phase
- 2,940
- Enrollment target
NCT07214519: Clinical Trial NA study, sponsored by NYU Langone Health.
NCT07214519 is a NA study that has not yet begun recruiting, run by NYU Langone Health. The registered enrollment target is 2,940 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (109% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07214519, a NA study, has not yet begun recruiting, sponsored by NYU Langone Health.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 2,940 participants
- Enrollment target
Study Summary
This community-partnered study examines a technical assistance intervention designed to help permanent supportive housing agencies implement evidence-based practices to prevent tenant overdose and improve tenant health.
Primary Outcome
Fidelity will be measured as the extent to which an intervention is implemented as intended by researchers; the specific method of measurement will be determined during the trial's preparatory phase, in consultation with multiple stakeholders. The measurement will comprise a composite score of multiple measures.
Interventions
- BEHAVIORAL TA Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,940 participants |
| Start Date | 2027-07-01 |
| Est. Completion | 2031-03-31 |
| Phase | NA |
What is known before NCT07214519 opens enrollment
NCT07214519 is an interventional study that assigns participants to a tested intervention. Its 2,940 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (109% higher).
The record links to 0 conditions, and to 1 intervention - of which TA Intervention is the first listed.
NCT07214519 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07214519 about?
NCT07214519 is a clinical study titled "Permanent Supportive Housing Overdose Prevention+ Study". This community-partnered study examines a technical assistance intervention designed to help permanent supportive housing agencies implement evidence-based practices to prevent tenant overdose and improve tenant health.
What is the current status of trial NCT07214519?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 2,940 participants. The study started on 2027-07-01. Estimated completion is 2031-03-31.
What interventions are being tested in trial NCT07214519?
The interventions under investigation include: TA Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT07214519?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07214519's enrollment target sits among peer trials
2,940 43rd of 2000 higher than 1,958 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05849961 · 2,946 participants
Exactech Hip Systems Post-Market Clinical Follow-up (PMCF)
- NCT03331380 · 2,950 participants · NA
Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System
- NCT05564377 · 2,900 participants · Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- NCT07222995 · 2,900 participants · NA
Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI